Anatibant
- Product NameAnatibant
- CAS209733-45-9
- CBNumberCB6855327
- MFC34H36Cl2N6O5S
- MW711.66
- MDL NumberMFCD09833920
- MOL File209733-45-9.mol
Chemical Properties
| Density | 1.44±0.1 g/cm3(Predicted) |
| pka | 14.09±0.46(Predicted) |
Anatibant Chemical Properties,Usage,Production
Uses
Anatibant (LF 16-0687; XY-2405) is a selective non-peptide bradykinin B2 receptor antagonist. Anatibant binds to the human, rat and guinea-pig recombinant B2 receptor with Ki values of 0.67 nM, 1.74 nM and 1.37 nM, respectively. Anatibant crosses the blood-brain barrier (BBB). Anatibant can be used in research on brain damage diseases[1][2].Definition
ChEBI: Anatibant is a proline derivative.in vivo
Anatibant (3 mg/kg; subcutaneous bolus; injection 15 min and 8 h after trauma, respectively) significantly reduces intracranial pressure (ICP) and of contusion volume 24 h after trauma in treated mice[1].
| Animal Model: | Male C57/Bl6 mice (25-28 g) were subjected to Controlled Cortical Impact trauma (CCI)[1] |
| Dosage: | 3 mg/kg |
| Administration: | Subcutaneous bolus; injection 15 min and 8 h after trauma, respectively |
| Result: | Demonstrated a significant reduction of ICP and of contusion volume 24 h after trauma in treated mice. |
IC 50
Bradykinin B2 Receptor (B2R): 0.67 nM (Ki, human recombinant B2 receptor); Bradykinin B2 Receptor (B2R): 1.74 nM (Ki, Rat recombinant B2 receptor); Bradykinin B2 Receptor (B2R): 1.37 nM (Ki, Guinea-pig recombinant B2 receptor)References
[1] Klaus Zweckberger, et al. Anatibant, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury. Neurosci Lett. 2009 Apr 24;454(2):115-7. DOI:10.1016/j.neulet.2009.02.014[2] D Pruneau, et al. Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. Immunopharmacology. 1999 Sep;43(2-3):187-94. DOI:10.1016/s0162-3109(99)00128-9
Anatibant Suppliers
Global(14)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| sales@conier.com | 49899 | 58 | |||
| +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | 32430 | 58 | ||
| 13564774135 | marketing@targetmol.com | 19950 | 58 | ||
| 13816107857 | sales@fortunechem-sh.com | 981 | 58 | ||
| +86-0519-85788828 +86-13775037613 | sales@chemrenpharm.com | 4081 | 58 | ||
| 15002134094 | marketing@targetmol.cn | 29874 | 58 | ||
| 15065661979 15065661979 | stonebiopharm@163.com | 1528 | 58 | ||
| 51288865780 | sales@biosynth.com | 6032 | 58 | ||
| +1(410) 997 5552 | sales@apacpharma.com | 6294 | 38 | ||
| 858 201 6118 | sales@acccorporation.com | 6793 | 51 |
209733-45-9(Anatibant) Related Search
1of4